



# Role of T Lymphocytes in HIV Neuropathogenesis

Caroline Subra<sup>1,2</sup> · Lydie Trautmann<sup>1,2</sup>

Published online: 6 May 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

## Abstract

**Purpose of Review** The purpose of this review is to summarize the current knowledge on the role of CD4<sup>+</sup> T lymphocytes leading to HIV assault and persistence in the central nervous system (CNS) and the elimination of HIV-infected CNS resident cells by CD8<sup>+</sup> T lymphocytes.

**Recent Findings** HIV targets the CNS early in infection, and HIV-infected individuals suffer from mild forms of neurological impairments even under antiretroviral therapy (ART). CD4<sup>+</sup> T cells and monocytes mediate HIV entry into the brain and constitute a source for HIV persistence and neuronal damage. HIV-specific CD8<sup>+</sup> T cells are also massively recruited in the CNS in acute infection to control viral replication but cannot eliminate HIV-infected cells within the CNS.

**Summary** This review summarizes the involvement of CD4<sup>+</sup> T cells in seeding and maintaining HIV infection in the brain and describes the involvement of CD8<sup>+</sup> T cells in HIV neuropathogenesis, playing a role still to be deciphered, either beneficial in eliminating HIV-infected cells or deleterious in releasing inflammatory cytokines.

**Keywords** HIV neuropathogenesis · T lymphocytes · CNS HIV invasion · HIV-infected cell killing · CNS inflammation

## Introduction

The advent of potent antiretroviral therapies has considerably reduced severe forms of dementia subsequent to HIV infection (HIV-associated dementia) and prolonged the life expectancy of HIV-infected individuals. However, individuals with long-term HIV are now facing complications, including mild forms of HIV-associated neurocognitive disorder (HAND) [1, 2]. Magnetic resonance spectroscopy, neuropsychological testing, and neuroimaging are used to diagnose neurologic dysfunction, including impairment in attention, learning, and executive functions that persists despite antiretroviral therapy (ART) [3, 4, 5, 6]. Impaired neurological performance is in part due to sustained immune activation and inflammation in successfully treated individuals [7]. Biomarkers such as neopterin (microglia activation) and neurofilament light chain

(neuronal breakdown) are increased in the cerebrospinal fluid (CSF) of HIV-infected individuals on suppressive therapy and indicate underlying neuroinflammation and neuronal damage [3, 8, 9, 10]. The lowest frequencies of neurological impairment have been described when ART is initiated before the CD4<sup>+</sup> T cell count drops to low levels, and, conversely, a low CD4 nadir count has been linked to higher risks of developing impairment [11]. A loss of neurons has been described in the majority of asymptomatic individuals even within 100 days post-infection [12]. Initiation of ART in acute infection (Fiebig I to II) [13] in HIV<sup>+</sup> individuals prevents severe neuronal damage after 6 months of treatment [14], avoids elevation and shedding of inflammation markers such as sCD163 [15], and confirms the benefit of initiating antiretroviral treatment early in the course of infection to prevent neuronal injury [16]. However, in some participants having high HIV RNA in the CSF prior to ART in acute infection, reduced neuropsychological performance is still observed [14].

The CSF provides an opportunity to study the events occurring in the central nervous system (CNS). Meningeal lymphatic vessels in the CNS drain CSF and participate in immune surveillance in the brain [17–20, 21]. T cells are the major cellular components of the CSF, and only 1 % of the T cells in the periphery have been estimated to be found in the CSF in physiological conditions [22]. Low-level T cell migration in the brain occurs in healthy individuals [23] as the CNS

This article is part of the Topical Collection on *Central Nervous System and Cognition*

✉ Lydie Trautmann  
ltrautmann@hivresearch.org

<sup>1</sup> Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA

<sup>2</sup> U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA

is an immune-privileged site where cell trafficking is controlled by the blood-brain barrier (BBB) and blood-CSF barrier. CD4<sup>+</sup> T cell trafficking is more frequent than CD8<sup>+</sup> T cells leading to a higher CD4/CD8 T cell ratio in CSF compared with blood [22, 24].

Following HIV-1 exposure, systemic inflammation and the virus itself are thought to trigger BBB disruption. HIV may enter the CNS freely [4], but the main source of infection of the CNS is believed to occur through infiltration of infected monocytes and T lymphocytes after alteration of the BBB [25, 26]. This review addresses the role of CD4<sup>+</sup> T lymphocytes compared with monocytes in mediating HIV infection in the brain and their contribution to the establishment of a viral reservoir and the persistence of inflammation. In HIV-infected individuals, CD8<sup>+</sup> T cells are predominantly present in the CSF pre- and post-ART with a lower CD4/CD8 T cell ratio [24, 27]. The massive CD8<sup>+</sup> T cell infiltration correlates with CSF HIV RNA in HIV-infected individuals of ART [24]. This review addresses the role of CD8<sup>+</sup> T cells in the elimination of HIV-infected cells in the brain and their potential implication as a contributor to neuronal damage.

## Source of Infection and Persistence

HIV RNA in the CSF can be detected as early as 8 days after the estimated day of infection [25, 26, 28]. A recent study sampling CSF in HIV-infected participants in acute infection evaluated HIV RNA in the CSF in 51% of participants at Fiebig I–II and 92% at Fiebig III–V. The detection of HIV RNA in plasma peaked at Fiebig III, whereas the peak of HIV RNA in the CSF was detected later at Fiebig IV [29]. Low-level HIV RNA can be detected in the CSF in about 40% of HIV-infected participants showing impaired neurocognitive performance during ART [8].

## Role of CD4<sup>+</sup> T Lymphocytes in HIV Entry into the CNS

Accumulating evidences support the theory that CD4<sup>+</sup> T cells may be critical for HIV entry in the meninges and in the choroid plexus during early infection [30]. Viral RNA loads in the CNS during the course of primary infection can be associated with CSF pleocytosis implying that the increase of HIV RNA may result from an increased number of infected CD4<sup>+</sup> T cells trafficking from the periphery into the CNS [31]. Transmitted/founder viruses have been found to be R5 T cell tropic strains requiring a high level of CD4 to enter the cells and are consequently poorly adapted to infect macrophages [22, 24]. Activated memory CCR5<sup>+</sup>CD4<sup>+</sup> T cells are the main targets of HIV in the blood. The CD4<sup>+</sup> T cells in the CSF represent about

300,000 cells for 150 ml of CSF in healthy individuals. In HIV-uninfected individuals, CD4<sup>+</sup> T cells are the main population found in the CSF, suggesting a preferential trafficking into the brain compared with the CD8<sup>+</sup> T cells, with a phenotype of activated central memory, and are thus highly susceptible to HIV infection [22, 24]. Initiation of ART triggers a rapid decay of viral load in the CSF in most individuals, implying that the main viral replication is sustained in short-lived cells such as CD4<sup>+</sup> T cells [22].

In rhesus macaques infected with SIVmac251, administration of natalizumab—a monoclonal antibody against  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrins—during early infection prevented T lymphocyte and monocyte infiltration across the endothelial cells in the brain and was associated with no detectable SIV RNA or SIV DNA in tissue brain sections in five out of six treated animals [32]. A late treatment 28 days after infection with natalizumab, however, only prevented monocyte/macrophage accumulation in the brain and stabilized the extent of neuronal damage. These observations underline the involvement of CD4<sup>+</sup> T lymphocytes in seeding the infection, while suggesting that monocytes may play a role in triggering and maintaining neuronal injury [32]. In line with these observations, a non-accelerated simian/human immunodeficiency virus (SHIV) model in rhesus macaques developed to reflect the early clinical course of HIV infection in humans recently demonstrated no accumulation of monocytes/macrophages in the CNS, while CD4<sup>+</sup> T lymphocytes were seen to infiltrate into the meningeal space in some animals at week 12 after infection [33]. SHIV RNA could also be detected in the brain parenchyma and meninges in some animals without any evidence of BBB disruption. Additionally, SHIV RNA-positive cells in the brain parenchyma and meninges could be detected, including in animals without CSF viremia. The inflammation mediated by the T cells concomitant to SHIV infection in the brain and meninges was proposed to be the source of early neurologic inflammation [33]. Corroborating these findings, the trafficking and the establishment of HIV infection in the brain by CD4<sup>+</sup> T cells have been demonstrated using BLT and T cell only humanized mice (ToM), in which human macrophages are absent [21]. After CNS entry, CD4<sup>+</sup> T cells may rapidly transmit the viruses that may integrate into perivascular macrophages and microglial cells, which are the major cells harboring HIV replication in the brain [28].

## Role of Myeloid Cells in HIV Entry into the CNS

An alternative hypothesis for HIV entry into the CNS pictures a Trojan horse model in which circulating HIV-infected monocytes mediate neuroinvasion and accumulate in the brain to then differentiate into perivascular macrophages. They harbor replication-competent viruses that lead to infection of resident cells and subsequent neuroinflammation and neuronal damage

[28, 34]. Activated non-classical CD14<sup>+</sup>CD16<sup>+</sup> monocytes present in blood increase from 6 to 40% in chronic HIV-infected individuals with low CD4 count and in a setting of AIDS dementia [35]. HIV DNA in CD14<sup>+</sup>CD16<sup>+</sup> monocytes has been found to be associated with neuropsychological performance in patients with HAND while on therapy [36]. These CD14<sup>+</sup>CD16<sup>+</sup> monocytes are thought to transmigrate through the BBB thanks to their high surface expression of CXCR5, CX3CR1, and integrin CD11b [4], junctional proteins, and chemokine receptors CCR2 [37], and CXCR7 [38]. The non-classical monocyte subset with low CD14 expression and high CD16 and CCR2 expression was found reduced in the periphery and was associated with worse neurocognitive performance in ART-naïve individuals [39]. Virally suppressed HIV-1-infected participants performed better after 24 weeks of treatment intensification with a dual CCR2/CCR5 antagonist [40]. Moreover, activated monocytes are able to secrete proinflammatory nano-sized vesicles that might transfer their content to endothelial cells and promote monocyte chemotaxis to the brain by increasing surface adhesion molecule expression [41].

### Role of CD4<sup>+</sup> T Cells and Myeloid Cells in Viral Reservoir Persistence

HIV can persist in CNS tissues despite successful control of systemic viral replication as suggested by the detection of CSF HIV RNA in neurologically stable individuals or asymptomatic individuals [28]. In successfully treated SIV-infected rhesus macaques, SIV RNA—positive cells were detected before but also after ART initiation in the brain [42••]. Because CD4<sup>+</sup> T cells are not frequent in the brain parenchyma, an alternate T cell reservoir may exist in the CNS compartment: the choroid plexus or lymphoid follicles in the meninges could participate in maintaining the infection [26]. Additionally, in an inflammatory environment, lipid mediators such as leukotrienes can be elevated in the CNS [43]. In vitro studies have revealed that exposure of astrocytes to leukotriene C4 elicits CX3CL1/Fractalkine production that acts as chemoattractant for activated CD4<sup>+</sup> T cells and enhances their migration across a BBB model. Hence, the sustained neuroinvasion of activated CD4<sup>+</sup> T cells could contribute to renew HIV target cells and to maintain HIV replication. When CD4<sup>+</sup> T cells are HIV-infected, their transmigration gives rise to productive infection of primary monocyte-derived macrophages sustaining replication in a stable reservoir [44]. Similarly, interferon-gamma inducible protein 10 (IP10), a potent chemoattractant for activated CD4<sup>+</sup> T cells, is elevated in CSF samples of HIV<sup>+</sup> individuals [45].

Over the course of infection, the virus evolves to become macrophage tropic [22, 46], and infection of macrophages, long-lived cells, leads to a productive infection that is not

cytopathic [47]. Thus, myeloid cells may play an important role in the HIV reservoir, contributing to driving persistent neuroinflammation and development of CNS lesions even after ART [48]. In virally suppressed SIV-infected pig-tailed macaques, a model for AIDS and HIV encephalitis with no detectable viral RNA in the brain, brain macrophages are found to be latently infected, able to be reactivated with latency reversal agents, and can produce competent viruses [49]. Consequently, both an influx of peripheral CD4<sup>+</sup> T cells and monocytes/macrophages could contribute to supporting a low level of infection in the CNS. HIV replication in the brain may also be supported at a low level by tissue perivascular and meningeal macrophages, as well as microglial cells. This replicating HIV could reseed the periphery and potentially lead to virological failure [3, 28]. It has recently been demonstrated that astrocytes can replicate viruses when in contact with lymphocytes or after stimulation by cytokines, and consequently they could also contribute to maintaining a reservoir [50]. Neurons and oligodendrocytes are not productively infected by HIV but can also harbor some virions and may participate in CNS pathogenesis [26, 47]. Resident cells release inflammatory cytokines, neurotoxic products, and viral proteins, thus sustaining neuronal damage [3, 26, 47].

### Role of the CD8<sup>+</sup> T Lymphocytes in HIV Neuropathogenesis

In HIV infection, CD8<sup>+</sup> T cells are known to massively infiltrate the CNS, a phenomenon only partially reversed by ART [24, 51•, 52•]. CD8<sup>+</sup> T cells may contribute to CNS immune surveillance by mediating the clearance of infected CD4<sup>+</sup> T cells, monocytes/macrophages, and resident cells. However, through the release of proinflammatory cytokines and chemokines, they may also contribute to sustaining the inflammatory environment and neuronal damage. In individuals on stable suppressive ART, a massive infiltration of CD8<sup>+</sup> T cells in the brain can even lead to CD8<sup>+</sup> T cell-associated encephalitis and trigger severe neurocognitive impairment and cerebral inflammation [27].

### Role of CD8<sup>+</sup> T Lymphocytes in Eliminating HIV-Infected Cells

The contribution of CD8<sup>+</sup> T lymphocytes in eliminating HIV-infected cells in the brain has been demonstrated in chronically SIV-infected rhesus monkeys after injection of a depleting anti-CD8<sup>+</sup> antibody into the CSF causing an increase in CSF viral load and an overall activation of microglia cells indicating viral replication [26, 53]. In another study, a unique subset of CD8<sup>+</sup> T cells expressing a low level of surface CD4 (CD4<sup>dim</sup>CD8<sup>bright</sup> T cells) displaying a terminally

differentiated phenotype and potent anti-HIV activity has been found in the brain of mice reconstituted with human peripheral blood mononuclear cells (PBMCs) [54•]. These cells appear to originate from the single CD8 expressing T cells, and their presence is associated with lower HIV content, implying that they may participate in the control of HIV infection. In SIV-infected macaques ART-treated at 4 days post-infection and successfully suppressed, a high number of CD8<sup>+</sup> T cells were identified in the basal ganglia [55], suggesting an enhanced trafficking of T lymphocytes into the brain after treatment in order to control HIV infection.

HIV-specific CD8<sup>+</sup> T cells with a memory phenotype have been detected in the CSF in ART-naïve viremic controllers and non-controllers [52]. Our group has also detected the presence of HIV-specific CD8<sup>+</sup> T cells in the CSF of HIV-infected participants in the acute phase of infection at peak viremia [51•]. These cells are derived from expansion of specific clonotypes compared with the periphery, suggesting compartmentalization of HIV-specific responses in the brain as early as acute infection [51•]. The presence of these activated cells containing HIV-specific CD8<sup>+</sup> T cells is associated with CSF viral load in acute infection but not with markers of neuronal damage, in contrast to chronic infection. These cells may eliminate HIV-infected cells in acute infection, as we showed in the periphery that HIV-specific CD8<sup>+</sup> T cells were associated with higher reduction of viral replication and lower reservoir seeding [56••]. The presence of HIV-specific CD8<sup>+</sup> T cells in CSF after successful ART has not been reported yet; therefore, their role in ART-suppressed individuals is unknown.

### Role of CD8<sup>+</sup> T Lymphocytes in CNS Inflammation and Damage

Though CD8<sup>+</sup> T cells are massively recruited in the brain, their capacity to eliminate CNS resident-infected cells still remains to be demonstrated. In the periphery, *ex vivo* experiments demonstrated that the killing capacities of circulating CD8<sup>+</sup> T cells toward HIV-infected macrophages appear to differ from the killing mechanism involved to eliminate HIV-infected CD4<sup>+</sup> T cells. Macrophage killing by CD8<sup>+</sup> T cells is impaired and triggers higher IFN- $\gamma$  secretion by CD8<sup>+</sup> T cells [57••]. CD8<sup>+</sup> T cells would therefore be less efficient in eliminating infected macrophages in the brain and would rather contribute to maintaining an inflammatory environment by activating macrophages through IFN- $\gamma$  secretion. Corroborating these latter observations, it has been recently shown that in *ex vivo* peripheral CD8<sup>+</sup> T cells from HIV-infected participants pre- and post-ART, a granzyme B response from HIV-specific CD8<sup>+</sup> T cells is linked to a reduction in the HIV reservoir instead of IFN- $\gamma$  production from HIV-specific CD8<sup>+</sup> T cells [58•]. Supporting this

notion, IFN- $\gamma$ -producing CD8<sup>+</sup> T cells recruited in the brain of individuals having detectable HIV RNA in the CSF are strongly correlated with severity of neurocognitive impairment. Their presence in CSF also positively correlates with the presence of HAND in successfully treated individuals [59]. A high frequency of constitutive IFN- $\gamma$ <sup>+</sup> expression in CD8<sup>+</sup> T cells endowed with low lytic capacities has also been found in a variety of neuroinflammatory diseases such as multiple sclerosis [59]. We have also shown that activated CD8<sup>+</sup> T cells in the CSF of chronically HIV-infected individuals exhibit gene expression profiles suggesting impaired effector functions and associate with soluble markers of neuronal damage [51•].

Several studies have highlighted an increase in activation markers on CD8<sup>+</sup> T cells during chronic HIV infection that associate with severity of neurocognitive impairment and persist under ART [60••, 61]. CD8<sup>+</sup> T cells with reduced cytolytic capacity are also associated with HAND in ART-naïve individuals, arguing for a deleterious role of CD8<sup>+</sup> T cells in neurocognitive impairment [61]. Of note, our group previously demonstrated a high level of activation and proliferation of circulating blood HIV-specific CD8<sup>+</sup> T cells in late acute HIV infection associated with mitochondrial dysfunction and a high oxidative profile leading to higher susceptibility to apoptosis [62] that could trigger cellular toxicity and immune activation and underlie neuronal damage and loss [63].

A massive T cell infiltration into the CNS, which is particularly important when ART is initiated in severely immunocompromised HIV-infected patients, can lead to encephalitis described as the central nervous system immune reconstitution inflammatory syndrome (CNS IRIS). CNS IRIS arises in virally suppressed ART-treated individuals who experience a deregulated immune response against a preexisting infection in the setting of CD4<sup>+</sup> T cell recovery, often highly detrimental for the host since it leads to neuronal damage, encephalopathy, demyelination, breakdown of the BBB, and progressive cerebral atrophy. This syndrome is estimated to develop in the CNS in 1% of ART-treated individuals [64]. CNS IRIS is characterized by a massive infiltration of activated CD4<sup>+</sup> T and CD8<sup>+</sup> T lymphocytes. In HIV and in the absence of opportunistic infection, CNS IRIS is mainly mediated by infiltration of CD8<sup>+</sup> T cells directed against HIV reservoirs or self-antigens [64]. Early intervention with ART appears to prevent the development of CNS IRIS.

### Conclusion

Early ART initiation has proven to considerably suppress viral replication and reduce neurocognitive impairment. Although it reduces the establishment of the HIV reservoir and limits immune damage, it does not completely eradicate the virus or fully restore the immune system. HIV targets the brain very

early in the course of infection via HIV-infected CD4<sup>+</sup> T cells and monocytes and establishes latency in resident long-lived cells. The relative contribution of CD4<sup>+</sup> T cells and monocytes in mediating HIV entry in the CNS at different stages of HIV infection still remains to be determined. The CNS thus represents a potential tissue sanctuary for HIV replication and leads to HIV compartmentalization. In addition, poor penetrance of certain antiviral drugs in the brain and development of drug resistance can lead to CNS HIV viral escape.

The increased trafficking of CD8<sup>+</sup> T cells into the CNS is subsequent to HIV invasion and may target local infected cells to contain the infection. Whether the HIV-specific CD8<sup>+</sup> T cells are able to reach, detect, and efficiently eliminate the infected cells in the CNS compartment is still questionable. CD8<sup>+</sup> T cells with high levels of activation but low cytolytic capacity have been identified and may contribute to damaging the CNS. Moreover, given the high inflammatory environment in the CNS during HIV infection, cytokine-driven proliferation of non-specific bystander cells may amplify a pathogenic role of CD8<sup>+</sup> T cells. Overall, the recruitment of activated and HIV-specific CD8<sup>+</sup> T cells in the brain may control viral replication in the early stages of HIV infection. However, their presence in later stages of infection and on ART, if functionally impaired or apoptotic, may be associated with detrimental effects to the CNS.

Determining the mechanisms leading to HIV infection in the brain and defining the beneficial or detrimental role of CD8<sup>+</sup> T cells in HIV neuropathogenesis are critical issues to address to develop new strategies to prevent HIV dissemination in the brain and CNS inflammation. To achieve improved control of infected cells while preventing CNS damage, a protective antiviral immunity might involve inducing HIV-specific functional T cells via immune therapeutic interventions. However, the impact on the brain of using immune modulators or immune intervention aiming at modifying cell trafficking and restoring HIV-specific CD8<sup>+</sup> T cell functions, or using latency reversing agents to reactivate latent virus in ART-treated participants needs to be carefully assessed.

**Funding Information** This work was supported by the U.S. National Institute of Mental Health R01MH106466 and by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD).

## Compliance with Ethical Standards

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Disclaimer** The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Saloner R, Cysique LA. HIV-associated neurocognitive disorders: a global perspective. *J Int Neuropsychol Soc.* 2017;23(9–10):860–9. <https://doi.org/10.1017/S1355617717001102>.
2. Spudich S. HIV and neurocognitive dysfunction. *Curr HIV/AIDS Rep.* 2013;10(3):235–43. <https://doi.org/10.1007/s11904-013-0171-y>.
3. Farhadian S, Patel P, Spudich S. Neurological complications of HIV infection. *Curr Infect Dis Rep.* 2017;19(12):50. <https://doi.org/10.1007/s11908-017-0606-5>.
4. Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. *Brain Behav Immun.* 2015;45:1–12. <https://doi.org/10.1016/j.bbi.2014.10.008>.
5. Do TC, Kerr SJ, Avihingsanon A, Suksawek S, Klungkang S, Channang T, et al. HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART. *J Virus Erad.* 2018;4(1):41–7. **This cross-sectional study evaluated the cognitive and psychomotor performance in well-suppressed HIV-infected Thai individuals after long-term treatment compared with healthy individuals.**
6. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. *Neurology.* 2010;75(23):2087–96. <https://doi.org/10.1212/WNL.0b013e318200d727>.
7. Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, et al. Plasma and cerebrospinal fluid biomarkers predict cerebral injury in HIV-infected individuals on stable combination antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2015;69(1):29–35. <https://doi.org/10.1097/QAI.0000000000000532>.
8. Anderson AM, Munoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, et al. Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. *J Infect Dis.* 2017;215(1):105–13. <https://doi.org/10.1093/infdis/jiw505> **In this study, the authors were able to detect a low level of HIV-1 RNA in the CSF of US HIV-infected participants under ART, using a sensitive detection method, and the discordant detection in the CSF compared with blood was associated with lower neurocognitive performance.**
9. Chan P, Hellmuth J, Spudich S, Valcour V. Cognitive impairment and persistent CNS injury in treated HIV. *Curr HIV/AIDS Rep.* 2016;13(4):209–17. <https://doi.org/10.1007/s11904-016-0319-7>.
10. Garvey LJ, Pavese N, Politis M, Ramlackhansingh A, Brooks DJ, Taylor-Robinson SD, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. *AIDS.* 2014;28(1):67–72. <https://doi.org/10.1097/01.aids.0000432467.54003.f7>.
11. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neuro-Oncol.* 2011;17(1):3–16. <https://doi.org/10.1007/s13365-010-0006-1>.

12. Ragin AB, Wu Y, Gao Y, Keating S, Du H, Sammet C, et al. Brain alterations within the first 100 days of HIV infection. *Ann Clin Transl Neurol.* 2015;2(1):12–21. <https://doi.org/10.1002/acn3.136>.
13. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. *AIDS.* 2003;17(13):1871–9. <https://doi.org/10.1097/01.aids.0000076308.76477.b8>.
14. Kore I, Ananworanich J, Valcour V, Fletcher JL, Chalermchai T, Paul R, et al. Neuropsychological impairment in acute HIV and the effect of immediate antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2015;70(4):393–9. <https://doi.org/10.1097/QAI.0000000000000746>.
15. D'Antoni ML, Byron MM, Chan P, Sailasuta N, Sacdalan C, Sithinamsuwan P, et al. Normalization of soluble CD163 after institution of antiretroviral therapy during acute HIV infection tracks with fewer neurological abnormalities. *J Infect Dis.* 2018;218:1453–63. <https://doi.org/10.1093/infdis/jiy337>.
16. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS.* 2011;25(14):1747–51. <https://doi.org/10.1097/QAD.0b013e32834a40cd>.
17. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. *Nature.* 2015;523(7560):337–41. <https://doi.org/10.1038/nature14432>.
18. Absinta M, Ha SK, Nair G, Sati P, Luciano NJ, Palisoc M, et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. *Elife.* 2017;6. <https://doi.org/10.7554/eLife.29738>.
19. Baruch K, Schwartz M. CNS-specific T cells shape brain function via the choroid plexus. *Brain Behav Immun.* 2013;34:11–6. <https://doi.org/10.1016/j.bbi.2013.04.002>.
20. Aspönd A, Antila S, Proulx ST, Karlén TV, Karaman S, Detmar M, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med.* 2015;212(7):991–9. <https://doi.org/10.1084/jem.20142290>.
21. Honeycutt JB, Liao B, Nixon CC, Cleary RA, Thayer WO, Birath SL, et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. *J Clin Invest.* 2018;128:2862–76. <https://doi.org/10.1172/JCI98968> **This study used two mouse models to demonstrate that CD4<sup>+</sup> T cells are sufficient to drive HIV infection in the brain.**
22. Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R. HIV-1 target cells in the CNS. *J Neuro-Oncol.* 2015;21(3):276–89. <https://doi.org/10.1007/s13365-014-0287-x>.
23. Smolders J, Remmerswaal EB, Schuurman KG, Melief J, van Eden CG, van Lier RA, et al. Characteristics of differentiated CD8(+) and CD4 (+) T cells present in the human brain. *Acta Neuropathol.* 2013;126(4):525–35. <https://doi.org/10.1007/s00401-013-1155-0>.
24. Ho EL, Ronquillo R, Altmeyen H, Spudich SS, Price RW, Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. *PLoS One.* 2013;8(6):e66188. <https://doi.org/10.1371/journal.pone.0066188>.
25. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central nervous system viral invasion and inflammation during acute HIV infection. *J Infect Dis.* 2012;206(2):275–82. <https://doi.org/10.1093/infdis/jis326>.
26. Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). *Curr HIV/AIDS Rep.* 2015;12(1):16–24. <https://doi.org/10.1007/s11904-014-0255-3>.
27. Spudich SS. Immune activation in the central nervous system throughout the course of HIV infection. *Curr Opin HIV AIDS.* 2016;11(2):226–33. <https://doi.org/10.1097/COH.0000000000000243>.
28. Hellmuth J, Valcour V, Spudich S. CNS reservoirs for HIV: implications for eradication. *J Virus Erad.* 2015;1(2):67–71.
29. Chan P, Patel P, Hellmuth J, Colby DJ, Kroon E, Sacdalan C, et al. Distribution of HIV RNA in CSF and blood is linked to CD4/CD8 ratio during acute HIV. *J Infect Dis.* 2018;218:937–45. <https://doi.org/10.1093/infdis/jiy260> **This study describes the detection of HIV RNA in CSF in most of the HIV individuals in acute infection and shows CSF HIV RNA peak at Fiebig IV subsequent to the peak in plasma.**
30. Spudich SS, Ances BM. CROI 2017: neurologic complications of HIV infection. *Top Antivir Med.* 2017;25(2):69–76.
31. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. *PLoS Pathog.* 2015;11(3):e1004720. <https://doi.org/10.1371/journal.ppat.1004720> **This study compared CSF and blood viral populations in ART-naïve subjects within 2 years post-HIV infection and demonstrated four different mechanisms in HIV brain infection in which both T cell pleocytosis and local viral replication in the CNS occur in early infection.**
32. Campbell JH, Ratai EM, Autissier P, Nolan DJ, Tse S, Miller AD, et al. Anti- $\alpha$ 4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. *PLoS Pathog.* 2014;10(12):e1004533. <https://doi.org/10.1371/journal.ppat.1004533>.
33. Hsu DC, Sunyakumthorn P, Wegner M, Schuetz A, Silsorn D, Estes JD, et al. Central nervous system inflammation and infection during early, non-accelerated simian-human immunodeficiency virus infection in rhesus macaques. *J Virol.* 2018;92:e00222–18. <https://doi.org/10.1128/JVI.00222-18> **This work addresses the very early events occurring in the brain after SIV infection and shows T cell infiltration without BBB damage.**
34. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. *Curr HIV Res.* 2014;12(2):85–96.
35. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. *Lancet.* 1997;349(9053):692–5. [https://doi.org/10.1016/S0140-6736\(96\)10178-1](https://doi.org/10.1016/S0140-6736(96)10178-1).
36. Kusao I, Shiramizu B, Liang CY, Grove J, Aagsalda M, Troelstrup D, et al. Cognitive performance related to HIV-1-infected monocytes. *J Neuropsychiatry Clin Neurosci.* 2012;24(1):71–80. <https://doi.org/10.1176/appi.neuropsych.11050109>.
37. Veenstra M, Leon-Rivera R, Li M, Gama L, Clements JE, Berman JW. Mechanisms of CNS viral seeding by HIV(+) CD14(+) CD16(+) monocytes: establishment and reseeded of viral reservoirs contributing to HIV-associated neurocognitive disorders. *MBio.* 2017;8(5). <https://doi.org/10.1128/mBio.01280-17>.
38. Veenstra M, Williams DW, Calderon TM, Anastos K, Morgello S, Berman JW. Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. *J Leukoc Biol.* 2017;102(5):1173–85. <https://doi.org/10.1189/jlb.3HI0517-167R>.
39. Ndhlovu LC, D'Antoni ML, Ananworanich J, Byron MM, Chalermchai T, Sithinamsuwan P, et al. Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais. *J Neuroimmunol.* 2015;288:25–33. <https://doi.org/10.1016/j.jneuroim.2015.08.020>.
40. D'Antoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E, et al. Improved cognitive performance and reduced monocyte activation in virally suppressed chronic HIV following dual CCR2 and CCR5 antagonism. *J Acquir Immune Defic Syndr.*

- 2018;79:108–16. <https://doi.org/10.1097/QAI.0000000000001752>.
41. Dalvi P, Sun B, Tang N, Pulliam L. Immune activated monocyte exosomes alter microRNAs in brain endothelial cells and initiate an inflammatory response through the TLR4/MyD88 pathway. *Sci Rep.* 2017;7(1):9954. <https://doi.org/10.1038/s41598-017-10449-0>.
  - 42.●● Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, et al. Defining total-body AIDS-virus burden with implications for curative strategies. *Nat Med.* 2017;23(11):1271–6. <https://doi.org/10.1038/nm.4411> **This study quantifies the viral reservoirs in many tissues and demonstrates the persistence of HIV RNA+ cells in the brain after ART in SIV-infected monkeys.**
  43. Haupts M, Smektala K, Finkbeiner T, Simmet T, Gehlen W. Immunoreactive leukotriene C4 levels in CSF of MS patients. *Acta Neurol Scand.* 1992;85(5):365–7.
  44. Bertin J, Jalaguier P, Barat C, Roy MA, Tremblay MJ. Exposure of human astrocytes to leukotriene C4 promotes a CX3CL1/fractalkine-mediated transmigration of HIV-1-infected CD4(+) T cells across an in vitro blood-brain barrier model. *Virology.* 2014;454-455:128–38. <https://doi.org/10.1016/j.virol.2014.02.007>.
  45. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. *J Neuroimmunol.* 1999;93(1–2):172–81.
  46. Beaulparlant D, Rusert P, Magnus C, Kadelka C, Weber J, Uhr T, et al. Delineating CD4 dependency of HIV-1: adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality. *PLoS Pathog.* 2017;13(3):e1006255. <https://doi.org/10.1371/journal.ppat.1006255>.
  47. Nath A. Eradication of human immunodeficiency virus from brain reservoirs. *J Neuro-Oncol.* 2015;21(3):227–34. <https://doi.org/10.1007/s13365-014-0291-1>.
  48. Mallard J, Williams K. An SIV macaque model of SIV and HAND: the need for adjunctive therapies in HIV that target activated monocytes and macrophages. *J Neuro-Oncol.* 2018;24(2):213–9. <https://doi.org/10.1007/s13365-018-0616-6>.
  49. Avalos CR, Abreu CM, Queen SE, Li M, Price S, Shirk EN, et al. Brain macrophages in simian immunodeficiency virus-infected, antiretroviral-suppressed macaques: a functional latent reservoir. *MBio.* 2017;8(4). <https://doi.org/10.1128/mBio.01186-17>.
  50. Barat C, Proust A, Deshiere A, Leboeuf M, Drouin J, Tremblay MJ. Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency. *Glia.* 2018;66:1363–81. <https://doi.org/10.1002/glia.23310>.
  - 51.● Kessing CF, Spudich S, Valcour V, Cartwright P, Chalermchai T, Fletcher JL, et al. High number of activated CD8+ T cells targeting HIV antigens are present in cerebrospinal fluid in acute HIV infection. *J Acquir Immune Defic Syndr.* 2017;75(1):108–17. <https://doi.org/10.1097/QAI.0000000000001301> **This study characterizes the CD8+ T lymphocytes in the CSF of HIV-infected participants during acute infection and demonstrates the presence of functional HIV-specific CD8+ T cells compared with untreated chronic infection.**
  - 52.● Ganesh A, Lemongello D, Lee E, Peterson J, McLaughlin BE, Ferre AL, et al. Immune activation and HIV-specific CD8(+) T cells in cerebrospinal fluid of HIV controllers and noncontrollers. *AIDS Res Hum Retrovir.* 2016;32(8):791–800. <https://doi.org/10.1089/AID.2015.0313> **This study evidenced the surveillance of CNS by CD8+ T cells and demonstrated the presence of HIV-specific CD8+ T cells in CSF samples of controller and non-controller HIV-infected individuals at similar frequency.**
  53. Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, et al. CD8(+) lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. *Immunity.* 2016;45(3):656–68. <https://doi.org/10.1016/j.immuni.2016.08.018>.
  - 54.● Richards MH, Narasipura SD, Seaton MS, Lutgen V, Al-Harthi L. Migration of CD8+ T cells into the central nervous system gives rise to highly potent anti-HIV CD4dimCD8bright T cells in a Wnt signaling-dependent manner. *J Immunol.* 2016;196(1):317–27. <https://doi.org/10.4049/jimmunol.1501394> **This study depicts a mice model reconstituted with human PBMCs and highlights a unique subset of potent anti-HIV CD8+ T cells expressing a low level of CD4 recruited in the brain.**
  55. Graham DR, Gama L, Queen SE, Li M, Brice AK, Kelly KM, et al. Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. *J Neuro-Oncol.* 2011;17(1):120–30. <https://doi.org/10.1007/s13365-010-0005-2>.
  - 56.●● Takata H, Buranapraditkun S, Kessing C, Fletcher JL, Muir R, Tardif V, et al. Delayed differentiation of potent effector CD8(+) T cells reducing viremia and reservoir seeding in acute HIV infection. *Sci Transl Med.* 2017;9(377):eaag1809. <https://doi.org/10.1126/scitranslmed.aag1809> **This study characterizes HIV-specific CD8+ T cells in a unique cohort of HIV-infected individuals in acute infection and demonstrates the presence of HIV-specific CD8+ T cells in controlling HIV replication in blood and limiting reservoir seeding.**
  - 57.●● Clayton KL, Collins DR, Lengieza J, Ghebremichael M, Dottiwala F, Lieberman J, et al. Resistance of HIV-infected macrophages to CD8(+) T lymphocyte-mediated killing drives activation of the immune system. *Nat Immunol.* 2018;19(5):475–86. <https://doi.org/10.1038/s41590-018-0085-3> **This study demonstrates a dichotomy in the capacity of CD8+ T cells to efficiently eliminate HIV-infected CD4+ T cells and macrophages and highlights an impaired macrophage killing leading to their activation and sustained inflammation.**
  - 58.● Yue FY, Cohen JC, Ho M, Rahman AK, Liu J, Mujib S, et al. HIV-specific granzyme B-secreting but not gamma interferon-secreting T cells are associated with reduced viral reservoirs in early HIV infection. *J Virol.* 2017;91(8). <https://doi.org/10.1128/JVI.02233-16> **This study examines INF-γ and granzyme B responses in PBMCs of HIV-infected individuals and demonstrates a granzyme B response from CD8+ T cells associated with a reduced viral reservoir.**
  59. Schrier RD, Hong S, Crescini M, Ellis R, Perez-Santiago J, Spina C, et al. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). *PLoS One.* 2015;10(2):e0116526. <https://doi.org/10.1371/journal.pone.0116526>.
  - 60.●● Grauer OM, Reichelt D, Gruneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, et al. Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. *Ann Clin Transl Neurol.* 2015;2(9):906–19. <https://doi.org/10.1002/acn3.227> **This study correlated increased frequency of activation markers on T lymphocytes in blood and in CSF with worse neurocognitive performance. A lower CD4/CD8 ratio was also associated with neurocognitive impairment.**
  61. Ratto-Kim S, Schuetz A, Sithinamsuwan P, Barber J, Hutchings N, Lerdlum S, et al. Characterization of cellular immune responses in Thai individuals with and without HIV-associated neurocognitive disorders. *AIDS Res Hum Retrovir.* 2018;34:685–9. <https://doi.org/10.1089/AID.2017.0237>.

62. Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. *Blood*. 2012;120(17):3466–77. <https://doi.org/10.1182/blood-2012-04-422550>.
63. Uzasci L, Nath A, Cotter R. Oxidative stress and the HIV-infected brain proteome. *J Neuroimmune Pharmacol*. 2013;8(5):1167–80. <https://doi.org/10.1007/s11481-013-9444-x>.
64. Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. *Curr Opin Neurol*. 2011;24(3):284–90. <https://doi.org/10.1097/WCO.0b013e328346be57>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.